NCT06327178Recruiting
Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.
Response to the Combination of Stereotactic Body Radiation Therapy and Concurrent PD-1 Blockade in Patients With Metastatic Renal Cell Carcinoma: a Retrospective Study
Source: ClinicalTrials.gov · Last updated 25 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response. The goal of this observational study is to learn about abscopal effects of stereotactic body radiotherapy and concurrent anti-PD-1 antibody treatment in patients of metastatic clear renal cell carcinoma. The primary objective was to assess the objective response rate (ORR) in non-irradiated lesions, and incidence of adverse events (AEs).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 11 Mar 2024
- Start date
- 1 Oct 2023
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Nanfang Hospital, Southern Medical University
- Diseases
- Kidney cancer
- NCT number
- NCT06327178
What you commit to
- Study type: Observational
- Planned participants: 20
- From 1 Oct 2023 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Has a known additional malignancy that is progressing or requires active treatment.
Other
- Patients who cannot be adequately followed up;
Who the study is looking for
- Age≥18 years at the time of signing informed consent;
- Histologically confirmed, advanced renal cell carcinoma of stage IV (AJCC 8);
- Previously received SBRT and concurrent PD-1 blockade treatment；
- Evidence of measurable metastatic kidney cancer according to RECIST 1.1 criteria.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanfang Hospital, Southern Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.